Author

C. Massey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

J. E. Comer· 2 shared A. Carston· 1 shared A. Drelich· 1 shared A. LeBeau· 1 shared A. N. Freiberg· 1 shared A. Odle· 1 shared A. Pinchuk· 1 shared A. S. Thickens· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. E. Comer

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor responsein prostate cancer

C. de Aguiar Ferreira, H. K. Potluri, C. Massey, J. J. Grudzinski, A. Carston, N. Clemons, A. S. Thickens, Z. Rosenkrans, C. Choi, A. Pinchuk, O. Kwon, J. J. Jeffery, B. Bednarz, Z. Morris, J. Weichert, , R. Hernandez

This study shows that 225Ac-NM600, an alpha-emitting radiopharmaceutical, enhances anti-tumor responses in prostate cancer by modulating the immune microenvironment.

bioRxiv · Sep 26, 2022 · PreprintImmunology

A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques

P. Harris, T. Brasel, C. Massey, C. Herst, S. Burkholz, P. Lloyd, T. Blankenberg, T. Bey, R. Carback, T. Hodge, S. Ciotlos, L. Wang, J. E. Comer, R. M. Rubsamen

A synthetic peptide vaccine targeting SARS-CoV-2 nucleocapsid protein protected rhesus macaques from viral challenge, reducing pneumonia and viral load.

bioRxiv · Apr 24, 2021Immunology

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

G. Ye, J. Gallant, C. Massey, K. Shi, W. Tai, J. Zheng, A. Odle, M. Vickers, J. Shang, Y. Wan, A. Drelich, K. Kempaiah, V. Tat, S. Perlman, L. Du, , F. Li

This paper develops a potent, low-cost nanobody therapeutic, Nanosota-1C-Fc, that effectively blocks SARS-CoV-2 infection in vitro and in vivo with high affinity and stability.

bioRxiv · Nov 17, 2020Microbiology

Pyronaridine Tetraphosphate Efficacy Against Ebola Virus Infection in Guinea Pig

T. R. Lane, C. Massey, J. E. Comer, A. N. Freiberg, H. Zhou, J. Dyall, M. Holbrook, M. Anantpadma, R. A. Davey, P. Madrid, S. Ekins

This paper evaluates pyronaridine tetraphosphate's efficacy against Ebola and Marburg viruses in guinea pigs, showing 40% survival and suggesting its potential for antiviral repurposing.

bioRxiv · Mar 20, 2020Pharmacology & Toxicology